Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia.
Vela-Ojeda J, García-Ruiz Esparza MA, Rosas-Cabral A, Padilla-González Y, García-Chávez J, Tripp-Villanueva F, Sánchez-Cortés E, Ayala-Sánchez M, García-León LD, Montiel-Cervantes L, Rubio-Borja ME. Vela-Ojeda J, et al. Ann Hematol. 2002 Jul;81(7):362-7. doi: 10.1007/s00277-002-0480-5. Epub 2002 Jun 25. Ann Hematol. 2002. PMID: 12185504 Clinical Trial.
Risk Factors for Thrombosis Development in Mexican Patients.
Zavala-Hernández C, Hernández-Zamora E, Martínez-Murillo C, Majluf-Cruz A, Vela-Ojeda J, García-Chávez J, Reyes-Maldonado E. Zavala-Hernández C, et al. Ann Vasc Surg. 2015 Nov;29(8):1625-32. doi: 10.1016/j.avsg.2015.05.035. Epub 2015 Aug 24. Ann Vasc Surg. 2015. PMID: 26315791
IFN-alpha as induction and maintenance treatment of patients newly diagnosed with Waldenström's macroglobulinemia.
Vela-Ojeda J, García-Ruiz Esparza MA, Padilla-González Y, Rosas-Cabral A, García-Chávez J, Xolotl-Castillo M, Salazar-Exaire D, Arenas-Osuna J, Aviña-Zubieta JA, Vadillo-Buenfil M, Abraham-Majluf S. Vela-Ojeda J, et al. J Interferon Cytokine Res. 2002 Oct;22(10):1013-6. doi: 10.1089/107999002760624233. J Interferon Cytokine Res. 2002. PMID: 12433280 Clinical Trial.
Allogeneic peripheral blood stem cell transplantation using reduced intensity versus myeloablative conditioning regimens for the treatment of leukemia.
Vela-Ojeda J, García-Ruiz Esparza MA, Tripp-Villanueva F, Ayala-Sánchez M, Delgado-Lamas JL, Garcés-Ruiz O, Rubio-Jurado B, Montiel-Cervantes L, Sánchez-Cortés E, García-Chavez J, Xolotl-Castillo M, Rosas-Cabral A, Salazar-Exaire D, Galindo-Rodríguez G, Aviña-Zubieta A. Vela-Ojeda J, et al. Stem Cells Dev. 2004 Oct;13(5):571-9. doi: 10.1089/scd.2004.13.571. Stem Cells Dev. 2004. PMID: 15588514
Clinical relevance of NKT cells and soluble MIC-A in Hodgkin lymphoma.
Vela-Ojeda J, Perez-Retiguin FDC, Olivas-Bejarano AC, Garcia-Ruiz Esparza MA, Garcia-Chavez J, Majluf-Cruz A, Reyes-Maldonado E, Montiel-Cervantes LA. Vela-Ojeda J, et al. Leuk Lymphoma. 2021 Apr;62(4):801-809. doi: 10.1080/10428194.2020.1852473. Epub 2020 Dec 7. Leuk Lymphoma. 2021. PMID: 33284055
49 results